| Autor: |
Labhardt, N. D., Smit, M., Petignat, I., Perneger, T., Marinosci, A., Ustero, P., Diniz Ribeiro, M. P., Ragozzino, S., Nicoletti, G. J., Faré, P. B., Andrey, D. O., Jacquerioz, F., Lebowitz, D., Agoritsas, T., Meyer, B., Spechbach, H., Salamun, J., Guessous, I., Chappuis, F., Kaiser, L., Decosterd, L. A., Grinsztejn, B., Bernasconi, E., Cardoso, S. W., Calmy, A., Team, Ftcs |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
EClinicalMedicine |
| Popis: |
Background Since the beginning of the COVID-19 pandemic, no direct antiviral treatment is effective as post-exposure prophylaxis (PEP). Lopinavir/ritonavir (LPV/r) was repurposed as a potential PEP agent against COVID-19. Methods We conducted a pragmatic open-label, parallel, cluster-randomised superiority trial in four sites in Switzerland and Brazil between March 2020 to March 2021. Clusters were randomised to receive LPV/r PEP (400/100 mg) twice daily for 5 days or no PEP (surveillance). Exposure to SARS-CoV-2 was defined as a close contact of >15 minutes in |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
